Literature DB >> 22282814

Facilitated cross-species transmission of prions in extraneural tissue.

Vincent Béringue1, Laëtitia Herzog, Emilie Jaumain, Fabienne Reine, Pierre Sibille, Annick Le Dur, Jean-Luc Vilotte, Hubert Laude.   

Abstract

Prions are infectious pathogens essentially composed of PrP(Sc), an abnormally folded form of the host-encoded prion protein PrP(C). Constrained steric interactions between PrP(Sc) and PrP(C) are thought to provide prions with species specificity and to control cross-species transmission into other host populations, including humans. We compared the ability of brain and lymphoid tissues from ovine and human PrP transgenic mice to replicate foreign, inefficiently transmitted prions. Lymphoid tissue was consistently more permissive than the brain to prions such as those causing chronic wasting disease and bovine spongiform encephalopathy. Furthermore, when the transmission barrier was overcome through strain shifting in the brain, a distinct agent propagated in the spleen, which retained the ability to infect the original host. Thus, prion cross-species transmission efficacy can exhibit a marked tissue dependence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282814     DOI: 10.1126/science.1215659

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  65 in total

1.  Post-conversion sialylation of prions in lymphoid tissues.

Authors:  Saurabh Srivastava; Natallia Makarava; Elizaveta Katorcha; Regina Savtchenko; Reinhard Brossmer; Ilia V Baskakov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

2.  PrP(Sc)-specific antibodies do not induce prion disease or misfolding of PrP(C) in highly susceptible Tga20 mice.

Authors:  Pekka Määttänen; Ryan Taschuk; Li Ross; Kristen Marciniuk; Lisa Bertram; Andrew Potter; Neil R Cashman; Scott Napper
Journal:  Prion       Date:  2013-10-08       Impact factor: 3.931

3.  Accelerated, spleen-based titration of variant Creutzfeldt-Jakob disease infectivity in transgenic mice expressing human prion protein with sensitivity comparable to that of survival time bioassay.

Authors:  Sophie Halliez; Fabienne Reine; Laetitia Herzog; Emilie Jaumain; Stéphane Haïk; Human Rezaei; Jean-Luc Vilotte; Hubert Laude; Vincent Béringue
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

4.  Stabilization of a prion strain of synthetic origin requires multiple serial passages.

Authors:  Natallia Makarava; Gabor G Kovacs; Regina Savtchenko; Irina Alexeeva; Herbert Budka; Robert G Rohwer; Ilia V Baskakov
Journal:  J Biol Chem       Date:  2012-07-17       Impact factor: 5.157

Review 5.  Role of lipid in forming an infectious prion?

Authors:  Fei Wang; Jiyan Ma
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-04-12       Impact factor: 3.848

6.  The many shades of prion strain adaptation.

Authors:  Ilia V Baskakov
Journal:  Prion       Date:  2014-02-11       Impact factor: 3.931

Review 7.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

Review 8.  Prions are affected by evolution at two levels.

Authors:  Reed B Wickner; Amy C Kelly
Journal:  Cell Mol Life Sci       Date:  2015-12-28       Impact factor: 9.261

Review 9.  Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.

Authors:  Julie A Moreno; Glenn C Telling
Journal:  Methods Mol Biol       Date:  2017

10.  Genetic depletion of complement receptors CD21/35 prevents terminal prion disease in a mouse model of chronic wasting disease.

Authors:  Brady Michel; Adam Ferguson; Theodore Johnson; Heather Bender; Crystal Meyerett-Reid; Bruce Pulford; Adriana von Teichman; Davis Seelig; John H Weis; Glenn C Telling; Adriano Aguzzi; Mark D Zabel
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.